In September 2024, SAGE's defined recommendations about two primary strategies for preventing severe RSV disease in infants: (a) Maternal Vaccination: Administering a single dose of RSV vaccine to pregnant women in their third trimester to protect their newborns through transplacental antibody transfer. This approach aims to reduce the incidence of severe RSV infections in infants during their first months of life. (b) Monoclonal Antibody Administration: Providing infants with a single dose of long-acting monoclonal antibodies at birth or just before the RSV season to offer direct protection against the virus. In March 2025, WHO prequalified the first maternal RSV vaccine, ABRYSVO®, developed by Pfizer. This prequalification facilitates the vaccine's procurement by UN agencies and supports its inclusion in global immunization programs.
Data are mostly derived from recent WHO and NITAGs official publications, peer reviewed papers and other sources ; or other institutional publications; data are not the result of a systematic review; data do not cover every aspect of the respective indicator. Users are encouraged to look at data sources in detail and any additional data that may be available (eg. regional and local)
